Latest Tumor markers Stories

Researchers from the Washington University School of Medicine in St. Louis claim to have discovered new evidence suggesting that obtaining an annual prostate cancer screening does not reduce mortality rate associated with the disease in older men. The study, which was published online in the Journal of the National Cancer Institute (JNCI) on Friday, looked at approximately 76,000 men between the ages of 55 and 74 participating in the Prostate, Lung, Cancer, Colorectal and Ovarian (PLCO)...

(Ivanhoe Newswire) – The U.S. Prostate Cancer Prevention Trial found cancer in many men with low levels of prostate specific antigen (PSA), and many debated which PSA level should lead to biopsy recommendation. The US Preventive Screening Task Force (USPSTF) recently concluded, amid considerable controversy, that the evidence does not support recommending PSA screening for men under 75 years old at all, because the risks outweigh the benefits. Now, a study shows that physicians in a...

No movement toward more aggressive follow-up, study in American Journal of Preventive Medicine finds After the US Prostate Cancer Prevention Trial found cancer in many men with low levels of prostate specific antigen (PSA), many debated which PSA level should lead to a biopsy recommendation. The US Preventive Screening Task Force (USPSTF) recently concluded, amid considerable controversy, that the evidence does not support recommending PSA screening for men under 75 years old at all,...

Women who inherit the cancer genes BRCA1 or BRCA2 from their paternal lineage may get a diagnosis a decade earlier than those women who carry the cancer genes from their mother and her ancestors, according to a new study by researchers at the North Shore-LIJ Health System's Monter Cancer Center in Lake Success, NY. The findings were reported on Thursday, Dec. 8, at the San Antonio Breast Cancer Symposium. Iuliana Shapira, MD, North director of cancer genetics, and her colleagues conducted...

Two studies available in the December issue of Hepatology, a journal of the American Association for the Study of Liver Diseases, have uncovered limitations in screening for primary liver cancer, also known as hepatocellular carcinoma (HCC). The first study found that, if given the choice during a clinical trial, most patients with cirrhosis prefer surveillance over the possibility of non-screening, therefore making a randomized study of HCC screening not feasible. A second study determined...

Tumors can grow for 10 years or longer before currently available blood tests will detect them, a new mathematical model developed by Stanford University School of Medicine scientists indicates. The analysis, which was restricted to ovarian tumors but is broadly applicable across all solid tumor types, will be published online Nov. 16 in Science Translational Medicine. "The study's results can be viewed as both bad and good news," said Sanjiv "Sam" Gambhir, MD, PhD, professor and chair of...

An international study describes a fundamental molecular mechanism in the development of breast cell epithelium that is altered in some breast cancer patients About 10% of breast cancers are due to mutations in genes called BRCA1 and BRCA2. However, the molecular mechanism by which alteration of these genes greatly increases the risk of cancer is not fully understood. In a new study, published Nov. 15 in the online, open-access journal PLoS Biology, an international team led by Miquel...

ATLANTA, Nov. 9, 2011 /PRNewswire-USNewswire/ -- Prostate cancer is the second leading cause of cancer mortality in men behind lung cancer. The PSA (prostate-specific antigen) blood test, even with limitations, is the best screening method we have today along with the DRE (digital rectal exam). Recently, the U.S. Preventive Services Task Force (USPSTF), a panel of non Urological/Oncological experts who review medical evidence for the government, published an open draft recommendation...

CAMBRIDGE, Mass., Nov. 2, 2011 /PRNewswire/ -- Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA(TM)) technology, announced that the analytical performance of its Prostate Specific Antigen (PSA) test, a fifth-generation digital immunoassay, demonstrated a 2-log improvement in sensitivity over today's ultrasensitive third-generation PSA assays used to measure PSA levels in patients following...

(Ivanhoe Newswire) – The largest study of its kind shows that women related to a patient with breast cancer caused by a hereditary mutation, but who don’t have the mutation themselves, have no higher risk of developing cancer than relatives of patients with other types of breast cancer. This contradicts previous research conducted four years ago that said that a familial BRCA mutation in and of itself was a risk factor. "The results are encouraging and reassuring," Allison Kurian, MD,...